Entacapone: Drug Safety Communication – FDA Review Found No Increased Cardiovascular Risks

Audience: Neurology Including Comtan (entacapone) and Stalevo (entacapone, carbidopa, and levodopa)
ISSUE: An FDA safety review has found no clear evidence of an increased risk of heart attacks, stroke, or other cardiovascular events associated…